Investigating how MIF and CD74 contribute to emphysema development
Role of MIF and CD74 in the pathogenesis of emphysema
This study is looking at how a protein called MIF might help protect lung cells from damage caused by smoking, with the goal of finding new ways to prevent or treat emphysema for people who are affected by this lung condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11009031 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of a protein called Macrophage Migration Inhibitory Factor (MIF) and its receptor CD74 in the development of emphysema, a severe lung condition often caused by smoking. The study aims to explore how MIF can protect lung cells from damage due to cigarette smoke and oxidative stress, which are key factors in the progression of emphysema. By examining the cellular responses to these harmful substances, the researchers hope to identify potential therapeutic targets that could help prevent or treat emphysema in patients. The approach includes both laboratory experiments and genetic studies in mice to uncover the protective mechanisms of MIF.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with a history of smoking who are at risk for developing emphysema or those already diagnosed with the condition.
Not a fit: Patients who do not smoke and have no risk factors for emphysema may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that prevent or slow the progression of emphysema in patients, particularly those affected by chronic smoking.
How similar studies have performed: Previous research has shown promising results in targeting MIF and its pathways for therapeutic purposes, indicating potential success for this approach.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Sauler, Maor — Yale University
- Study coordinator: Sauler, Maor
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.